Interferon alpha-2: Clinical Trials

4 trials of Interferon alpha-2, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 terminated. 4 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Terminated 4
Phase 23Terminated 3

Follow Interferon alpha-2: new trials by email Literature Review of Interferon alpha-2 trials Research Report on Interferon alpha-2

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Biopsy, Biospecimen Collection, Celecoxib - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Phase 1 / Phase 2TerminatedRoswell Park Cancer Institute52024-02-162026-08-31
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Recombinant Interferon Alfa-2b, Rintatolimod - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Phase 1 / Phase 2TerminatedRoswell Park Cancer Institute42020-11-172026-01-13
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
Ipilimumab, Temozolomide, Cisplatin - Melanoma
Phase 1TerminatedM.D. Anderson Cancer Center192013-02-012017-05-31
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Chemokin Modulatory Regimen (5 MU/m2), Chemokin Modulatory Regimen (10 MU/m2), Chemokin Modulatory Regimen (20 MU/m2) - Colorectal Cancer, Colorectal Carcinoma
Phase 1 / Phase 2TerminatedRoswell Park Cancer Institute152012-10-012023-10-27

Conditions studied

Neoplasm Metastasis (2)  ·  Colorectal Neoplasms (1)  ·  Hematologic Neoplasms (1)  ·  Melanoma (1)  ·  Recurrence (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

Roswell Park Cancer Institute (3)  ·  M.D. Anderson Cancer Center (1)

Countries

United States (4)

Top investigators

Amer H Zureikat, MD (1)  ·  Ellis Levine, MD (1)  ·  Igor Puzanov (1)  ·  Rodabe N. Amaria, MD (1)

NIH funding

P01CA234212 (1), P30CA016056 (1)